Parkinson’s Disease (DNL201)

Official Title

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 30-75
Inclusion Clinical diagnosis of Parkinson's disease. Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive.
Exclusion Any history of clinically significant asthma, chronic obstructive pulmonary disease, or emphysema within 5 years of screening, or other clinically significant pulmonary disease within 6 months of screening. Clinically significant neurologic disorder other than Parkinson's disease, including history of stroke, cognitive impairment, seizure within 5 years of screening, or head trauma with loss of consciousness within 6 months of screening.
Start Date
Compensation Variable
Location Orlando, FL

Study Information

Condition Parkinson's

Administrative Information

Study ID Neurological

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.